Linked Life Data

15542204

Source:http://linkedlifedata.com/resource/pubmed/id/15542204

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2004-11-15
pubmed:abstractText
Intranasal (i.n.) vaccination represents an attractive non-invasive alternative to needle-based injection and provides superior protection at mucosal surfaces. However, new formulations are needed to improve efficacy and reduce the refrigerated storage and distribution requirements associated with standard liquid vaccines. Here, we describe a powder formulation of whole inactivated influenza virus and a novel i.n. delivery platform. The powder-formulated vaccine elicited a significant serum antibody response in rats that was at least as strong as that provided by the liquid vaccine administered i.n. or via intramuscular (i.m.) injection. Significant nasal IgA responses were also observed solely after i.n. delivery. This study demonstrates for the first time the generation of potent nasal mucosal and systemic immune responses using an i.n. delivered influenza vaccine powder and suggests an alternative approach to vaccination against influenza and other infectious diseases.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
21
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
794-801
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.
pubmed:affiliation
BD Technologies, 21 Davis Drive, Research Triangle Park, NC 27709, USA.
pubmed:publicationType
Journal Article